Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.7K
Overview
64.7K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K
Inflammatory Response01:28

Inflammatory Response

12.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
12.5K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Immunological Memory01:23

Immunological Memory

12.3K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
12.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental Assessment of Two Non-Contrast MRI Sequences Used for Computational Fluid Dynamics: Investigation of Consistency Between Techniques.

Cardiovascular engineering and technology·2020
Same author

Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents.

PloS one·2018
Same author

Antemortem biomarker support for a diagnosis of clinically probable chronic traumatic encephalopathy.

Molecular psychiatry·2017
Same author

Cerebral [<sup>18</sup> F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.

Translational psychiatry·2016
Same author

Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Δexon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology.

Molecular psychiatry·2016
Same author

Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Δexon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology.

Molecular psychiatry·2015
Same journal

Adult-Onset LRBA Deficiency Presenting with Rheumatoid Arthritis-Like Manifestations: A Case Report.

Journal of clinical immunology·2026
Same journal

Immunopathological Profile of Patients with Thymic Epithelial Tumour and Good Syndrome in Advanced Stage.

Journal of clinical immunology·2026
Same journal

Facial Dysmorphism and Severe Vascular Phenotype in TRNT1 Deficiency with Concomitant Antithrombin III Deficiency.

Journal of clinical immunology·2026
Same journal

Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.

Journal of clinical immunology·2026
Same journal

Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.

Journal of clinical immunology·2026
Same journal

Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center.

Journal of clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

936

Immunomodulation and AD--down but not out.

E M Knight1, S Gandy

  • 1Departments of Neurology and Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, 10029, USA, elysse.knight@mssm.edu.

Journal of Clinical Immunology
|May 1, 2014
PubMed
Summary
This summary is machine-generated.

Intravenous immunoglobulin (IVIG) showed cognitive stabilization in Alzheimer's disease (AD) patients with the APOE ε4 allele, but did not improve daily living activities, failing to meet trial outcomes.

More Related Videos

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

626

Related Experiment Videos

Last Updated: Apr 30, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

936
Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

9.0K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

626

Area of Science:

  • Neurodegenerative diseases
  • Immunotherapy
  • Alzheimer's disease (AD) research

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) plaques.
  • Current Aβ-targeting immunotherapies show limited clinical efficacy despite success in animal models.
  • Intravenous immunoglobulin (IVIG) has been investigated as a potential AD treatment.

Purpose of the Study:

  • To evaluate the efficacy of IVIG in a Phase 3 clinical trial for Alzheimer's disease.
  • To identify potential therapeutic components within IVIG for AD treatment.

Main Methods:

  • A Phase 3 clinical trial was conducted to assess IVIG's impact on AD patients.
  • Cognitive function and activities of daily living were primary outcome measures.

Main Results:

  • The IVIG trial did not meet its primary efficacy endpoints for overall AD patient population.
  • A statistically significant cognitive stabilization was observed in moderate-stage AD patients carrying the APOE ε4 allele.
  • No significant benefit was found in activities of daily living for any patient group.

Conclusions:

  • IVIG did not demonstrate broad efficacy for Alzheimer's disease in this Phase 3 trial.
  • The APOE ε4 allele may identify a subgroup of AD patients who could benefit cognitively from IVIG.
  • Further research is needed to identify specific active components in IVIG for targeted AD therapy development.